Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.31 |
| ▸ | CPB1 | P15086 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7653761 | 0.94 | SMN1; SMN2 (0.34) | SMN1; SMN2CYP4F2CYP4A11ALDH1A1DDAH1 | |
| SCHEMBL5830472 | 0.94 | SMN1; SMN2 (0.34) | SMN1; SMN2CYP4F2CYP4A11ALDH1A1DDAH1 | |
| SCHEMBL445610 | 0.84 | SMN1; SMN2 (0.40) | SMN1; SMN2CYP4F2CYP4A11CPB2CPB1 | |
| SCHEMBL14996288 | 0.84 | SMN1; SMN2 (0.40) | SMN1; SMN2CYP4F2CYP4A11CPB2CPB1 | |
| SCHEMBL7647468 | 0.83 | PPARG (0.43) | ALDH1A1DDAH1CPB2CPB1TSHR | |
| SCHEMBL7367907 | 0.81 | DDAH1 (0.33) | DDAH1CA2 | |
| SCHEMBL16246663 | 0.81 | ALDH1A1 (0.43) | SMN1; SMN2CYP4F2CYP4A11ALDH1A1CPB2 | |
| SCHEMBL27525591 | 0.81 | ALDH1A1 (0.33) | ALDH1A1DDAH1 | |
| SCHEMBL3204334 | 0.80 | SMN1; SMN2 (0.33) | SMN1; SMN2CYP4F2CYP4A11PPARA | |
| SCHEMBL7647510 | 0.80 | CA2 (0.42) | DDAH1CPB2CPB1CA2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20220185785-A1 | INHIBITORS OF CD40-CD154 BINDING | TONIX Pharmaceuticals Holding Corp (US) | 2022-06-16 | — | — | US | disclosed |
| CN-114173772-A | Inhibitors of CD40-CD154 binding | 托尼克斯医药控股公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3952853-A1 | INHIBITORS OF CD40-CD154 BINDING | Tonix Pharmaceuticals Holding Corp. (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2020210831-A1 | INHIBITORS OF CD40-CD154 BINDING | TONIX Pharmaceuticals Holding Corp (US) | 2020-10-15 | — | — | WO | disclosed |
| US-7683196-B2 | Isocyanate-free primer composition for glass and glass ceramics | SIKA TECHNOLOGY AG (CH) | 2010-03-23 | — | — | US | disclosed |
| US-20070043196-A1 | Isocyanate-free primer composition for glass and glass ceramics | SIKA TECHNOLOGY AG (CH) | 2007-02-22 | — | — | US | disclosed |
| US-6350795-B1 | ACOUSTIC PHASE-CHANGE CONDUCTIVE INK CONTAINING LOW MOLECULAR WEIGHT OXYALKYLENE SEGMENTS COMPLEXED WITH UREA DERIVATIVES | XEROX CORPORATION | 2002-02-26 | — | — | US | disclosed |
| US-6096125-A | Ink compositions | XEROX CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185785-A1 | INHIBITORS OF CD40-CD154 BINDING | CD40LG, CD40, CD4 | SMN1; SMN2 3984/4885CYP4F2 810/4885CYP4A11 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.